Table A9.

Multivariate Analysis Including Post-Treatment SUV_peak (institutional read) as a Variable, After Excluding Patients With Post-Treatment PET Scans Done < 12 or > 16 Weeks After Radiotherapy (n = 61)

Parameter	Hazard Ratio	95% CI	P
Age (years): continuous	1.008	0.980 to 1.037	.585
Sex: female v male	1.024	0.611 to 1.717	.927
Performance status: ambulatory, capable of light work v fully active	1.460	0.889 to 2.396	.135
Clinical stage
IIIA v IIB	1.161	0.267 to 5.059	.842
IIIB v IIB	1.539	0.343 to 6.911	.574
Radiotherapy dose (Gy): continuous	0.982	0.932 to 1.034	.494
Chemotherapy regimen
Cisplatin + etoposide v carboplatin + paclitaxel	0.778	0.369 to 1.640	.510
Other v carboplatin + paclitaxel	1.240	0.714 to 2.152	.445
Post-treatment SUVpeak: continuous	1.092	0.973 to 1.225	.134

Abbreviations: PET, positron emission tomography; SUV_peak, peak standardized uptake value.